Published in Pain on October 04, 2005
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci (2007) 2.78
Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun (2006) 1.67
Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics (2009) 1.36
Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics (2009) 1.24
Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol (2007) 1.21
The analgesic potential of cannabinoids. J Opioid Manag (2010) 1.16
Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther (2008) 1.10
Dynamic changes to the endocannabinoid system in models of chronic pain. Philos Trans R Soc Lond B Biol Sci (2012) 0.96
Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury. Exp Neurol (2006) 0.90
Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol (2014) 0.88
Effects of alterations in cannabinoid signaling, alone and in combination with morphine, on pain-elicited and pain-suppressed behavior in mice. J Pharmacol Exp Ther (2012) 0.86
Effects of morphine on pain-elicited and pain-suppressed behavior in CB1 knockout and wildtype mice. Psychopharmacology (Berl) (2011) 0.85
Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery. Mol Pain (2014) 0.84
Effect of ethyl pyruvate on Paclitaxel-induced neuropathic pain in rats. Korean J Pain (2013) 0.82
Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain. Br J Pharmacol (2009) 0.80
The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology (2017) 0.78
A cannabinoid pharmacotherapy for chemotherapy-evoked painful peripheral neuropathy. Pain (2005) 0.78
Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity. Br J Pharmacol (2007) 0.76
Coadministration of indomethacin and minocycline attenuates established paclitaxel-induced neuropathic thermal hyperalgesia: Involvement of cannabinoid CB1 receptors. Sci Rep (2015) 0.76
Single and combined effects of delta(9) -tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. Br J Pharmacol (2017) 0.75
Effects of Taxol on Regeneration in a Rat Sciatic Nerve Transection Model. Sci Rep (2017) 0.75
Long-acting fentanyl analogues: synthesis and pharmacology of N-(1-phenylpyrazolyl)-N-(1-phenylalkyl-4-piperidyl)propanamides. Bioorg Med Chem (2002) 1.20
Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. Pain (2007) 1.09
WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci (2007) 0.90
Guanidinium and aminoimidazolinium derivatives of N-(4-piperidyl)propanamides as potential ligands for mu opioid and I2-imidazoline receptors: synthesis and pharmacological screening. Bioorg Med Chem (2002) 0.90
Radiological study of gastrointestinal motor activity after acute cisplatin in the rat. Temporal relationship with pica. Auton Neurosci (2008) 0.89
Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells. Eur J Pharmacol (2012) 0.88
Characterization of cannabinoid-induced relief of neuropathic pain in a rat model of cisplatin-induced neuropathy. Pharmacol Biochem Behav (2013) 0.87
TRAIL/TRAIL receptor system and susceptibility to multiple sclerosis. PLoS One (2011) 0.86
Risk acceptance in multiple sclerosis patients on natalizumab treatment. PLoS One (2013) 0.86
Antinociceptive effect of three common analgesic drugs on peripheral neuropathy induced by paclitaxel in rats. Pharmacol Biochem Behav (2010) 0.84
Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests. Eur J Pain (2009) 0.81
Age-related changes in the gastrointestinal tract: a functional and immunohistochemical study in guinea-pig ileum. Life Sci (2007) 0.80
Anandamide vehicles: a comparative study. Eur J Pharmacol (2004) 0.80
Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes. Pharmacol Biochem Behav (2012) 0.79
Antiobesity designed multiple ligands: Synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents. Bioorg Med Chem (2008) 0.79
Evaluation of the effect of age on cannabinoid receptor functionality and expression in guinea-pig ileum longitudinal muscle-myenteric plexus preparations. Neurosci Lett (2005) 0.77
Structural-activity relationship study on C-4 carbon atom of the CB1 antagonist SR141716: synthesis and pharmacological evaluation of 1,2,4-triazole-3-carboxamides. Eur J Med Chem (2005) 0.77
Synthesis and opioid activity of new fentanyl analogs. Life Sci (2002) 0.75
New benzimidazole derivatives: selective and orally active 5-HT3 receptor antagonists. Eur J Pharmacol (2003) 0.75
Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide. Eur J Med Chem (2009) 0.75
Synthesis and analgesic activity of a series of new azaalkane bis-guanidinium and bis(2-aminoimidazolinium) compounds. Bioorg Med Chem (2003) 0.75
Discovery of 1,1-dioxo-1,2,6-thiadiazine-5-carboxamide derivatives as cannabinoid-like molecules with agonist and antagonist activity. Bioorg Med Chem (2007) 0.75